Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNN vs DXCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: SNN 2 – 4 DXCM Matrix Metrics: SNN 3 – 7 DXCM

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNN carries a Unified Composite Score of 36.9/100 (SELL) at $29.83 (12.6x Forward P/E, 14.2% operating margin), whereas DXCM carries 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin).

  • Technical & Structure Timing Caution: SNN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.5); meanwhile DXCM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNN vs DXCM
SNN NYSE
Smith & Nephew plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$29.83
+0.0% 1D
Market Cap $12.5B
TTM Revenue $6.30B
Forward P/E 12.6x
Beta / 30D Vol 0.27β · 32% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 39.0 Fund 36.0 Flow 50.0 Mom 16.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.5 · SMA20: $30.68 · SMA50: $28.97
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94

6-Pillar Scorecard Institutional Category Breakdown (SNN 2 – 4 DXCM)

Columns: Metric · SNN · DXCM
1. Valuation Multiples SNN
Forward P/E 12.6x 25.3x
Trailing P/E 20.3x 31.6x
PEG Ratio 1.11x 1.30x
EV / Revenue 2.0x 5.9x
2. Growth & Scale DXCM
Revenue Growth (YoY) +4.6% +11.2%
Earnings Growth (YoY) +5.7% +2.6%
TTM Revenue (USD) $6.30B $5.10B
Market Cap $12.5B $29.9B
3. Profitability & Quality DXCM
Gross Margin 68.4% 63.4%
Operating Margin 14.2% 24.0%
Net Profit Margin 10.1% 19.4%
Return on Equity (ROE) 11.8% 37.7%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.38B EBITDA $1.73B
Cash Flow Margin 21.9% EBITDA Mgn 33.9%
Net Cash / Leverage $2.43 Book/Sh · 11.8% ROE $432M Net Debt (0.55x D/E)
Dividend Yield 2.66% None (0.00%)
5. Options & Positioning DXCM
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 19.6% (50th %ile) 63.0% (15th %ile)
Put/Call OI Skew Thin ADR Chain 0.48x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat SNN
OpEx & R&D Intensity 54.2% of Rev ($3.41B) 39.4% of Rev ($2.01B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNN (3) vs DXCM (7)
Institutional Metric SNN DXCM Criterion Row Edge
Market Capitalization
Scale
$12.5B $29.9B Larger Scale DXCM
Trailing P/E Ratio
Valuation
20.3x 31.6x Lower Multiple SNN
Forward P/E Ratio
Valuation
12.6x 25.3x Lower Multiple SNN
Revenue Growth (YoY)
Growth
+4.6% +11.2% Higher Growth DXCM
Operating Margin (TTM)
Profitability
14.2% 24.0% Higher Margin DXCM
Net Profit Margin
Profitability
10.1% 19.4% Higher Margin DXCM
Return on Equity (ROE)
Capital Efficiency
11.8% 37.7% Higher ROE DXCM
52-Week Range Position
Momentum
34% ($26–$37) 63% ($57–$93) Stronger Trend DXCM
Beta / 30D Volatility
Risk Regime
0.27β · 32% Vol 0.59β · 43% Vol Lower Realized Risk SNN
Unified Institutional Score
Composite Signal
36.9 / 100 (SELL) 50.8 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$6.30B $5.10B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.4% 63.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.11x PEG · 2.0x EV/Rev 1.30x PEG · 5.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.38B EBITDA ($2.43 Book/Sh · 11.8% ROE) $1.73B ($432M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DXCM +4.68 pp
SNN: -3.4% · DXCM: +1.28%
3M Horizon SNN +13.6 pp
SNN: +0.71% · DXCM: -12.89%
6M Horizon DXCM +12.3 pp
SNN: -2.29% · DXCM: +10.01%
1Y Horizon DXCM +40.39 pp
SNN: -7.59% · DXCM: +32.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SNN vs DXCM. Trailing 12-month operating profitability (SNN 14.2% vs DXCM 24.0%) and valuation multiples (SNN 12.6x vs DXCM 25.3x Forward P/E) are benchmarked directly in Pillar 4 below.

SNN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.30B
Gross Margin68.4%
Op. Margin14.2%
ROE / Fwd P/E11.8% · 12.6x
DXCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.10B
Gross Margin63.4%
Op. Margin24.0%
ROE / Fwd P/E37.7% · 25.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 19.6%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($8,161)

Compare $8,161 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 39.6% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $85 / $75 Bear Put Spread

Buy 1x $85P · Sell 1x $75P · 31d

Net Entry $380 Debit
T+5d @ -5% Drop +$186 (+49%)
Max Risk / Buffer $380 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.5B market capitalization and 14.2% operating margin.
OpEx & R&D Reinvestment 54.2% of Rev ($3.41B)
90D Engineering Disclosures 0 Published
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published

Investor FAQ SNN vs DXCM Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Smith & Nephew plc (SNN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNN carries a Unified Composite Score of 36.9/100 (SELL) at $29.83 (12.6x Forward P/E, 14.2% operating margin), whereas DXCM carries 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin). Technical & Structure Timing Caution: SNN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.5); meanwhile DXCM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: SNN posts +4.6% YoY revenue growth and +5.7% YoY earnings growth on $6.30B TTM revenue (68.4% gross margin, 14.2% operating margin), compared with DXCM at +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin). On trailing 12-month operating scale, SNN generates $6.30B in USD-normalized revenue versus $5.10B for DXCM. In operating R&D and SG&A reinvestment, SNN deploys 54.2% of Rev ($3.41B) (0 90-day corporate R&D disclosures) versus 39.4% of Rev ($2.01B) (0 disclosures) for DXCM.

SNN screens cheaper on headline valuation multiples. SNN trades at 12.6x Forward P/E, 20.3x Trailing P/E, 1.11x PEG, and 2.0x EV/Revenue (21.9% EBITDA margin), whereas DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNN (11.8% ROE) versus DXCM (37.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SNN carries 19.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 32% Vol realized risk). By comparison, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.